Capturing circulating tumor data in RWD: A new frontier for cancer research
Cancer is an insidious disease. Even after surgery or aggressive systemic therapy, malignant cells often take refuge in hard-to-identify places in the body before emerging again to cause recurring illness. For many years, researchers have been looking for more effective, less invasive ways to spot residual cancer cells after therapy to better gauge the impact […]
RWD and the FDA: Top trends to watch for pharma companies
The FDA plays an incredibly important role in the process of developing, distributing, and monitoring therapeutic products. So when something changes at the FDA, the entire life sciences community sits up and takes notice. In recent months, those changes have come fast and furious as the new administration seeks to put its priorities into action. […]
The power of platforms: How data companies can accelerate the use of quality RWD for clinical research
Not all data platforms are created equal, and not all data companies are employing the same techniques to produce reliable and consistent results, notes a recent white paper from the Clinical Research Data Sharing Alliance (CRDSA).
Real world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA)
Amer Methqal Zeidan, Leyla Hernandez Donoso, Sejla Hodzic, Henry F Owusu, Dhrubajyoti Pathak, Summera Qiheng Zhou, Eytan Stein
How to use real world clinicogenomic data to fuel drug development
This blog series talks extensively about the benefits of using real-world data (RWD) to enhance clinical trials and accelerate research into new therapies for a variety of different conditions. Now it s time to take a closer look at the details.
COTA Deloitte On Data Biases
Host Sandy Leonard sits down with experts Laura Fernandes and Sesh Srinivasan to dive into the pressing issue of bias in clinical research.
